🏢 官网IRDYNCodex · 实盘不做把握 6/10
北京时间·🕒 发布 10:46:53时区推断·⟳ 抓取 10:47:46·⚡ 决策 07-22 10:50:06 +2m20s·97.2 天前
Dyne Therapeutics 定价上调后公开增发 3.75 亿美元普通股
公司以每股20.50美元发行1830万股，募资3.7515亿美元，较7月21日收盘价23.82美元折价约13.9%，短线对现有股东形成明确稀释与定价锚。
📄 原文DYN↗ 原文
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
Skip to main navigation Skip to main content Open navigation About Us FORCE TM Platform Pipeline Physicians Patients In…
不做 Dyne Therapeutics（DYN.US）
事件方向偏空，但盘后价格已跌至20.50美元发行价附近，主要稀释冲击已price-in；同时未确认可借券，不能满足做空红线，当前不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 媒体报道Dyne此前宣布3亿美元股权发行，股价盘后大跌，说明融资利空在定价稿前已开始传播。市场反应:报道称DYN在发行消息后下跌16.1%。
- 公司正式确认扩大发行规模至1830万股、每股20.50美元、总募资3.7515亿美元，预计7月23日完成。市场反应:官方定价价位成为次日交易锚。
- 行情页显示DYN 7月21日收盘23.82美元，盘后20.50美元，跌幅约13.94%。市场反应:盘后价格已基本贴近发行价20.50美元。
关键理由
- 公司以每股20.50美元发行1830万股，募资3.7515亿美元，较7月21日收盘价23.82美元折价约13.9%，短线对现有股东形成明确稀释与定价锚。
- 该股盘后已跌至20.50美元，基本贴近本次发行价，主要负面冲击已在盘后交易中释放。
主要风险
- 若次日开盘低于发行价且承销稳定买盘不足，仍可能继续承压；但未能确认可借券，不能给可执行空单。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-07-21 · 影响 weakens
未获得可借券数量确认，且盘后价已贴近20.50美元发行价，继续追空的边际空间不足。
检索:Dyne Therapeutics offering after hours price 20.50 borrow short availability 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-07-21 · 影响 weakens
近期DYNE-251被FDA审评及卖方峰值销售预期构成中期利好背景，但不能抵消本次折价增发的短线稀释利空。
检索:Dyne Therapeutics FDA review DYNE-251 analyst peak sales July 2026 原文 ↗
原文全文
展开原文 · 7,481 字
Skip to main navigation
Skip to main content
Open navigation
About Us
FORCE TM Platform
Pipeline
Physicians
Patients
Investors & Media
Culture & Careers
Overview
Leadership
Board of directors
Scientific advisory board
Corporate Responsibility
Contact us
about-us
Overview
Scientific publications & presentations
force™-platform
Overview
Zeleciment rostudirsen (DYNE-251)
Zeleciment basivarsen (DYNE-101)
DYNE-302
pipeline
physicians
Commitment
Clinical trials
DMD stories
DM1 stories
FSHD stories
Resources
patients
Company overview
News, publications & events
Stock information
Corporate governance
Financials & filings
IR resources
investors--media
Our culture & values
Hear from our Dynamos
Competitive benefits
Open positions
culture--careers
Stay in Touch
info@dyne-tx.com
781.786.8230
781.786.8230
linkedin.com
twitter.com
facebook.com
youtube.com
Poised to address unmet need in neuromuscular diseases and
positioned for growth
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
July 21, 2026
PDF Version
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of $20.50 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $375,150,000. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 23, 2026, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,745,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also acting as joint book-running managers for the offering. Jones is acting as lead manager for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com ; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com ; LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com; or Raymond James & Associates, Inc., at 880 Carillon Parkway, St. Petersburg, Florida 33716, Attention: Equity Syndicate, by calling toll-free at 1-800-248-8863, or emailing at prospectus@raymondjames.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the anticipated closing date of the public offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks and uncertainties related to the satisfaction of customary closing conditions for the public offering and other factors discussed in the “Risk Factors” section of the preliminary prospectus supplement filed with the SEC on July 21, 2026, as well as the risks and uncertainties identified in Dyne’s filings with the SEC, including Dyne’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
back to news
Print
Contact IR
RSS
Email Alerts
Stay in touch
info@dyne-tx.com
781.786.8230
781.786.8230
linkedin.com
twitter.com
facebook.com
youtube.com
Privacy Policy
© 2026 Dyne Therapeutics, Inc.
You are now leaving
the Dyne Therapeutics corporate website
Continue Stay on page
Skip to main content
Open navigation
About Us
FORCE TM Platform
Pipeline
Physicians
Patients
Investors & Media
Culture & Careers
Overview
Leadership
Board of directors
Scientific advisory board
Corporate Responsibility
Contact us
about-us
Overview
Scientific publications & presentations
force™-platform
Overview
Zeleciment rostudirsen (DYNE-251)
Zeleciment basivarsen (DYNE-101)
DYNE-302
pipeline
physicians
Commitment
Clinical trials
DMD stories
DM1 stories
FSHD stories
Resources
patients
Company overview
News, publications & events
Stock information
Corporate governance
Financials & filings
IR resources
investors--media
Our culture & values
Hear from our Dynamos
Competitive benefits
Open positions
culture--careers
Stay in Touch
info@dyne-tx.com
781.786.8230
781.786.8230
linkedin.com
twitter.com
facebook.com
youtube.com
Poised to address unmet need in neuromuscular diseases and
positioned for growth
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
July 21, 2026
PDF Version
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of $20.50 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $375,150,000. All shares in the offering are being sold by Dyne. The offering is expected to close on or about July 23, 2026, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 2,745,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.
Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also acting as joint book-running managers for the offering. Jones is acting as lead manager for the offering.
The offering is being made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. This offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. A final prospectus supplement relating to the offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com ; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com ; LifeSci Capital LLC, Attention: LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, NY 10019, or by email at legalnotices@lifescicapital.com; or Raymond James & Associates, Inc., at 880 Carillon Parkway, St. Petersburg, Florida 33716, Attention: Equity Syndicate, by calling toll-free at 1-800-248-8863, or emailing at prospectus@raymondjames.com.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this press release, including statements relating to the anticipated closing date of the public offering, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” or “would,” or the negative of these terms, or other comparable terminology are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Dyne may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including the risks and uncertainties related to the satisfaction of customary closing conditions for the public offering and other factors discussed in the “Risk Factors” section of the preliminary prospectus supplement filed with the SEC on July 21, 2026, as well as the risks and uncertainties identified in Dyne’s filings with the SEC, including Dyne’s most recent Form 10-Q and in subsequent filings Dyne may make with the SEC. In addition, the forward-looking statements included in this press release represent Dyne’s views as of the date of this press release. Dyne anticipates that subsequent events and developments will cause its views to change. However, while Dyne may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Dyne’s views as of any date subsequent to the date of this press release.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
back to news
Contact IR
RSS
Email Alerts
Stay in touch
info@dyne-tx.com
781.786.8230
781.786.8230
linkedin.com
twitter.com
facebook.com
youtube.com
Privacy Policy
© 2026 Dyne Therapeutics, Inc.
You are now leaving
the Dyne Therapeutics corporate website
Continue Stay on page
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。